Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

Ítems similars

• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  per: Tseng, Jeng-Sen, et al.
  Publicat: (2016)
• Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
  per: Tseng, Jeng-Sen, et al.
  Publicat: (2014)
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  per: Mok, T.S., et al.
  Publicat: (2016)
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
  per: Su, Kang-Yi, et al.
  Publicat: (2018)
• Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
  per: Zong-Han Yao, et al.
  Publicat: (2025-08-01)